NEW OPPORTUNITIES OF TREATMENT OF DIFFERENT TYPES OF JUVENILE ARTHRITIS WITH MONOCLONAL ANTIBODIES TO THE INTERLEUKIN 6 RECEPTOR
Abstract
The article observes the data on the role of interleukin (IL) 6 in pathogenesis of rheumatoid arthritis and treatment of rheumatoid arthritis and different types of juvenile arthritis with blocker IL 6 receptor (tocilizumab). The data on multicenter open-labeled and double-blinded randomized studies on effectiveness and safety of tocilizumab are reviewed. The results of studies showed high effectiveness and safety of tocilizumab in treatment of rheumatoid arthritis and juvenile arthritis.
Key words: children, rheumatoid arthritis, juvenile arthritis, interleukin 6, treatment, tocilizumab.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(1):52-61)
About the Authors
E.I. AlexeevaRussian Federation
R.V. Denisova
Russian Federation
S.I. Valieva
Russian Federation
T.M. Bzarova
Russian Federation
A.O. Lisitsyn
Russian Federation
Review
For citations:
Alexeeva E., Denisova R., Valieva S., Bzarova T., Lisitsyn A. NEW OPPORTUNITIES OF TREATMENT OF DIFFERENT TYPES OF JUVENILE ARTHRITIS WITH MONOCLONAL ANTIBODIES TO THE INTERLEUKIN 6 RECEPTOR. Current Pediatrics. 2010;9(1):52-61.
Email this article 
